Therapeutic Asset Ratings

1,996 results matching 1 filter

129,439 assets · 8,701 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Ibrutinib CCND3 Positive	M.D. Anderson Cancer Center	P2	CCC (53)
Idarubicin Acute Myeloid Leukemia, Inv(16)(P13.1;Q22)	M.D. Anderson Cancer Center	P2	CCC (53)
Idarubicin Acute Myeloid Leukemia, T(16;16)(P13.1;Q22)	M.D. Anderson Cancer Center	P2	CCC (53)
Idarubicin Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1	M.D. Anderson Cancer Center	P2	CCC (53)
Idarubicin Myelodysplastic Syndrome With Excess Blasts-2	M.D. Anderson Cancer Center	P2	CCC (53)
Idarubicin Myeloid Sarcoma	M.D. Anderson Cancer Center	P2	CCC (53)
Idarubicin Philadelphia Chromosome Positive	M.D. Anderson Cancer Center	P2	CCC (53)
IMMUNOGLOBULIN G1, ANTI-(HUMAN 5'-NUCLEOTIDASE) (HUMAN MONOCLONAL MEDI9447 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL MEDI9447 .LAMBDA.-CHAIN, DIMER Malignant Pancreatic Neoplasm	M.D. Anderson Cancer Center	P2	CCC (53)
Immunoglobulin G1 [de-C-terminal-lysine], anti-(human CC chemokine receptor CCR8) (human-Mus musculus monoclonal BMS-986340 ?1-chain), disulfide with human-Mus musculus monoclonal BMS-986340 ?-chain, dimer Nivolumab	M.D. Anderson Cancer Center	P2	CCC (53)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Acute Myeloid Leukemia With 11q23 Abnormalities	M.D. Anderson Cancer Center	P2	CCC (53)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Acute Myeloid Leukemia With BCR-ABL1	M.D. Anderson Cancer Center	P2	CCC (53)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Acute Myeloid Leukemia With Multilineage Dysplasia	M.D. Anderson Cancer Center	P2	CCC (53)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER CCND1 Positive	M.D. Anderson Cancer Center	P2	CCC (53)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER CCND1 Protein Overexpression	M.D. Anderson Cancer Center	P2	CCC (53)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER CCND2 Positive	M.D. Anderson Cancer Center	P2	CCC (53)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER CCND3 Positive	M.D. Anderson Cancer Center	P2	CCC (53)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER FCER2 Negative	M.D. Anderson Cancer Center	P2	CCC (53)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER t(11;14)(q13;q32)	M.D. Anderson Cancer Center	P2	CCC (53)
IMMUNOGLOBULIN HALF-IG G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS CTLA4 (CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4, CD152)) AND ANTI-(HOMO SAPIENSPDCD1 (PROGRAMMED CELL DEATH 1, PD-1, PD1, CD279)), MONOCLONAL ANTIBODY, BISPECIFIC Cervical Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
IMMUNOGLOBULIN HALF-IG G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS CTLA4 (CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4, CD152)) AND ANTI-(HOMO SAPIENSPDCD1 (PROGRAMMED CELL DEATH 1, PD-1, PD1, CD279)), MONOCLONAL ANTIBODY, BISPECIFIC High Grade Malignant Neoplasm	M.D. Anderson Cancer Center	P2	CCC (53)
IMMUNOGLOBULIN HALF-IG G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS CTLA4 (CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4, CD152)) AND ANTI-(HOMO SAPIENSPDCD1 (PROGRAMMED CELL DEATH 1, PD-1, PD1, CD279)), MONOCLONAL ANTIBODY, BISPECIFIC Hodgkins Lymphoma	M.D. Anderson Cancer Center	P2	CCC (53)
IMMUNOGLOBULIN HALF-IG G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS CTLA4 (CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4, CD152)) AND ANTI-(HOMO SAPIENSPDCD1 (PROGRAMMED CELL DEATH 1, PD-1, PD1, CD279)), MONOCLONAL ANTIBODY, BISPECIFIC Malignant Pleural Mesothelioma	M.D. Anderson Cancer Center	P2	CCC (53)
IMMUNOGLOBULIN HALF-IG G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS CTLA4 (CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4, CD152)) AND ANTI-(HOMO SAPIENSPDCD1 (PROGRAMMED CELL DEATH 1, PD-1, PD1, CD279)), MONOCLONAL ANTIBODY, BISPECIFIC Microsatellite High Cancers	M.D. Anderson Cancer Center	P2	CCC (53)
IMMUNOGLOBULIN HALF-IG G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS CTLA4 (CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4, CD152)) AND ANTI-(HOMO SAPIENSPDCD1 (PROGRAMMED CELL DEATH 1, PD-1, PD1, CD279)), MONOCLONAL ANTIBODY, BISPECIFIC Peritoneal Mesothelioma	M.D. Anderson Cancer Center	P2	CCC (53)
IMMUNOGLOBULIN HALF-IG G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS CTLA4 (CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4, CD152)) AND ANTI-(HOMO SAPIENSPDCD1 (PROGRAMMED CELL DEATH 1, PD-1, PD1, CD279)), MONOCLONAL ANTIBODY, BISPECIFIC Rectal Cancer	M.D. Anderson Cancer Center	P2	CCC (53)

Showing 776 to 800 of 1,996 assets

PreviousPage 32 of 80Next